Other substances

Vitamin D3

A steroid hormone. 

Phase of research

Potential treatment - clinical evidence

How it helps

Other treatment

Drug status

Used to treat other disease

2
 Supporting references
0
 Contradictory references
53
 AI-suggested references
65
 Clinical trials

General information

Vitamin D3 is a steroid hormone produced in the skin when exposed to ultraviolet light or obtained from dietary sources. The active form of vitamin D3, 1,25-dihydroxycholecalciferol (calcitriol) plays an important role in maintaining blood calcium and phosphorus levels and mineralization of bone. The activated form of cholecalciferol binds to vitamin D receptors and modulates gene expression. This leads to an increase in serum calcium concentrations by increasing intestinal absorption of phosphorus and calcium, promoting distal renal tubular reabsorption of calcium and increasing osteoclastic resorption (NCIt).

Vitamin D3 on DrugBank
Vitamin D3 on PubChem
Vitamin D3 on Wikipedia

Synonyms

Cholecalciferol; calciol; vitamin D

Marketed as

ADROVANCE; DELTA-D; LUXA-D; MICRO-D; OPTIMAL-D; VIDEXTRA; VIGANTOL; VITAMIN D

 

Structure image - Vitamin D3

CC(C)CCCC(C)C1CCC2C1(CCCC2=CC=C3CC(CCC3=C)O)C

Supporting references

Link Tested on Impact factor Notes Publication date
A cohort study to evaluate the effect of combination Vitamin D, Magnesium and Vitamin B12 (DMB) on progression to severe outcome in older COVID-19 patients.
Preprint Cohort study 		Patients

used as vitamin D3 1000 IU OD, magnesium 150mg OD and vitamin B12 500mcg OD upon admission when not requiring oxygen therapy

 Jun/10/2020
Short term, high-dose vitamin D supplementation for COVID-19 disease: a randomised, placebo-controlled, study (SHADE study)
Asymptomatic Small molecule Randomized controlled single-blind trial Mild severity 		Vitamin D deficient asymptomatic to mild patients 1.91

Patients with 25(OH)D levels <20 ng/ml were supplemented with vitamin D with the intention to reach plasma levels of >50 ng/ml which was achieved in 10/16 patients in the treatment group by day 7 and 12/16 by day 14 from the start of the treatment. A significantly higher number of treated patients achieved SARS-CoV-2 RNA negativity compared to placebo control group. Significant decrease of plasma fibrinogen (but not other inflammatory markers) was observed, as well. Sample size: 16 + 16 placebo. Dosage: 60,000 IU daily for 14 days.


 Nov/12/2020

AI-suggested references

Link Publication date
Nutrition, Immune Function, and Infectious Disease.
Nov/25/2021
l-Cysteine Stimulates the Effect of Vitamin D on Inhibition of Oxidative Stress, IL-8, and MCP-1 Secretion in High Glucose Treated Monocytes.
Feb/17/2021
Vitamin D (Cholecalciferol) with Low Dose Vitamin C as a Safe and Effective Therapeutic Modality in an Adult with COVID-19 Pneumonia.
Jun/26/2020
Potential role of flavonoids against SARS-CoV-2 induced diarrhea.
May/31/2021
Vitamin D3 and its hydroxyderivatives as promising drugs against COVID-19: a computational study.
Aug/20/2021
Promising therapeutic approach for SARS-CoV-2 infection by using a rutin-based combination therapy.
May/24/2022
Home-based aerobic training and vitamin D improve neurotrophins and inflammatory biomarkers in MS patients.
Feb/19/2022
High-dose vitamin D versus placebo to prevent complications in COVID-19 patients: Multicentre randomized controlled clinical trial.
May/27/2022
Molecular Simulations suggest Vitamins, Retinoids and Steroids as Ligands of the Free Fatty Acid Pocket of the SARS-CoV-2 Spike Protein**
Dec/30/2021
A Single Large Dose of Vitamin D Could be Used as a Means of Coronavirus Disease 2019 Prevention and Treatment.
Aug/21/2020
Impact of daily high dose oral vitamin D therapy on the inflammatory markers in patients with COVID 19 disease
Feb/08/2021
Vitamin D Intake May Reduce SARS-CoV-2 Infection Morbidity in Health Care Workers.
Jan/24/2022
Changes in the immune response against SARS-CoV-2 in individuals with severe COVID-19 treated with high dose of vitamin D
Apr/14/2022
A large-scale computational screen identifies strong potential inhibitors for disrupting SARS-CoV-2 S-protein and human ACE2 interaction
May/17/2021
Dexamethasone treatment may mitigate adverse effects of vitamin D deficiency in hospitalized Covid-19 patients Dexamethasone treatment May mitigate adverse effects of vitamin D deficiency in hospitalised Covid-19 patients
May/30/2021
A Five-Ingredient Nutritional Supplement and Home-Based Resistance Exercise Improve Lean Mass and Strength in Free-Living Elderly
Mar/05/2021
Dexamethasone and Nutraceutical Therapy Can Reduce the Myalgia Due to COVID-19 - a Systemic Review of the Active Substances that Can Reduce the Expression of Interlukin-6.
Apr/16/2022
The History of Methylprednisolone, Ascorbic Acid, Thiamine, and Heparin Protocol and I-MASK+ Ivermectin Protocol for COVID-19.
Apr/06/2021
Cohort study to evaluate the effect of vitamin D, magnesium, and vitamin B12 in combination on progression to severe outcomes in older patients with coronavirus (COVID-19)
Jan/22/2022
High-dose vitamin D substitution in patients with COVID-19: study protocol for a randomized, double-blind, placebo-controlled, multi-center study:VitCov Trial
Dec/30/2021
Effect of a Single High Dose of Vitamin D3 on Hospital Length of Stay in Patients With Moderate to Severe COVID-19: A Randomized Clinical Trial.
Feb/17/2021
Unravelling Vitamin B12 as a potential inhibitor against SARS-CoV-2: A computational approach
Aug/14/2021
Can a Combination of AT1R Antagonist and Vitamin D Treat the Lung Complication of COVID-19?
Jul/15/2020
Effect of a Single High-Dose Vitamin D3 on the Length of Hospital Stay of Severely 25-Hydroxyvitamin D-Deficient Patients with COVID-19.
Nov/17/2021
Vitamin D receptor stimulation to reduce acute respiratory distress syndrome (ARDS) in patients with coronavirus SARS-CoV-2 infections
Jan/01/2021
Age and vitamin D affect the magnitude of the antibody response to the first dose of the SARS-CoV-2 BNT162b2 vaccine
Mar/16/2022
Vitamin D Supplementation Associated to Better Survival in Hospitalized Frail Elderly COVID-19 Patients: The GERIA-COVID Quasi-Experimental Study
Mar/05/2022
Network Pharmacology and Bioinformatics Analyses Identify Intersection Genes of Vitamin D3 and COVID-19 as Potential Therapeutic Targets
Apr/28/2022
Multi-omics-based identification of SARS-CoV-2 infection biology and candidate drugs against COVID-19.
Oct/10/2020
Treatment With 25-Hydroxyvitamin D3 (Calcifediol) Is Associated With a Reduction in the Blood Neutrophil-to-Lymphocyte Ratio Marker of Disease Severity in Hospitalized Patients With COVID-19: A Pilot Multicenter, Randomized, Placebo-Controlled, Double-Bli
Oct/13/2021
Calcifediol treatment and COVID-19-related outcomes
Aug/06/2021
A single-oral bolus of 100,000 IU of cholecalciferol at hospital admission did not improve outcomes in the COVID-19 disease: the COVID-VIT-D:a randomised multicentre international clinical trial
Dec/01/2020
High-Dose Cholecalciferol Booster Therapy is Associated with a Reduced Risk of Mortality in Patients with COVID-19: A Cross-Sectional Multi-Centre Observational Study
Jun/16/2020
Cytokine storm modulation in COVID-19: a proposed role for vitamin D and DPP-4 inhibitor combination therapy (VIDPP-4i)
Apr/28/2021
Discovery of re-purposed drugs that slow SARS-CoV-2 replication in human cells
Oct/15/2021
Effects of a 2-Week 5000 IU versus 1000 IU Vitamin D3 Supplementation on Recovery of Symptoms in Patients with Mild to Moderate Covid-19: A Randomized Clinical Trial
Jun/24/2021
Harnessing adenosine A2A receptors as a strategy for suppressing the lung inflammation and thrombotic complications of COVID-19: Potential of pentoxifylline and dipyridamole
Jul/02/2020
Vitamin D and lumisterol novel metabolites can inhibit SARS-CoV-2 replication machinery enzymes
Oct/26/2021
Vitamin D: A simpler alternative to tocilizumab for trial in COVID-19?
Apr/23/2020
Association of Calcitriol Supplementation with Reduced COVID-19 Mortality in Patients with Chronic Kidney Disease: A Population-Based Study.
May/05/2021
Effectiveness of In-Hospital Cholecalciferol Use on Clinical Outcomes in Comorbid COVID-19 Patients: A Hypothesis-Generating Study
Jul/20/2020
Tripartite Combination of Candidate Pandemic Mitigation Agents: Vitamin D, Quercetin, and Estradiol Manifest Properties of Medicinal Agents for Targeted Mitigation of the COVID-19 Pandemic Defined by Genomics-Guided Tracing of SARS-CoV-2 Targets in Human
May/21/2020
Vitamin D Supplementation in COVID-19 Patients: A Clinical Case Series
Aug/18/2020
The effect of high-dose parenteral vitamin D3 on COVID-19-related inhospital mortality in critical COVID-19 patients during intensive care unit admission: an observational cohort study.
Jul/23/2021
Efficacy and Safety of Vitamin D Supplementation to Prevent COVID-19 in Frontline Healthcare Workers. A Randomized Clinical Trial
Feb/09/2022
Effect of a single high dose of Vitamin D3 on cytokines, chemokines and growth factor in patients with moderate to severe COVID-19
Aug/30/2021
A Network-Based Analysis Reveals the Mechanism Underlying Vitamin D in Suppressing Cytokine Storm and Virus in SARS-CoV-2 Infection
May/11/2020
Vitamin D supplementation prior to or during COVID-19 associated with better 3-month survival in geriatric patients: Extension phase of the GERIA-COVID study.
Jul/29/2021
Therapies to Prevent Progression of COVID-19, Including Hydroxychloroquine, Azithromycin, Zinc, and Vitamin D3 With or Without Intravenous Vitamin C: An International, Multicenter, Randomized Trial
Apr/01/2021
"Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study".
Aug/29/2020
Use of repurposed and adjuvant drugs in hospital patients with covid-19: multinational network cohort study.
May/11/2021
Rapid and Effective Vitamin D Supplementation May Present Better Clinical Outcomes in COVID-19 (SARS-CoV-2) Patients by Altering Serum INOS1, IL1B, IFNg, Cathelicidin-LL37, and ICAM1
Nov/12/2021
A randomized pilot study using calcitriol in hospitalized COVID-19 patients.
Sep/08/2021

Clinical trials

ID Title Status Phase Start date Completion date
NCT04636086 Effect of Vitamin D on Hospitalized Adults With COVID-19 Infection Recruiting Phase 4 Nov/12/2020 Feb/28/2023
  • Alternative id - D-COVID
  • Interventions - Drug: Cholecalciferol|Other: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - CHU Liège, Liège, Belgium
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
  • Enrollment - 100
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Vitamin D serum concentration|Clinical improvement|Hospital length of stay.|Intensive care unit length of stay.|Supplemental oxygen, non-invasive or invasive ventilation or organ support|Duration of supplemental oxygen, non-invasive or invasive ventilation or organ support|Absence of fever|Time until negative laboratory SARS-CoV-2 test.|Mortality all causes.|Mortality related to Covid-19.|Biological markers
NCT04769297 Micro-Dose, Macro-Impact: Leveraging Psychedelics in Frontline Healthcare Workers During the COVID-19 Pandemic Active, not recruiting Phase 4 Apr/15/2020 Apr/01/2021
  • Alternative id - LM-LDK-001
  • Interventions - Drug: Sublingual Micro-Dose Ketamine
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Limbic Medical, Toluca Lake, California, United States
  • Study designs - Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 30
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Patient self-reported outcome measure
NCT04334005 Vitamin D on Prevention and Treatment of COVID-19 Not yet recruiting Not Applicable Apr/10/2020 Jun/30/2020
  • Alternative id - COVITD-19
  • Interventions - Dietary Supplement: Vitamin D
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Universidad de Granada, Granada, Andalucia, Spain|Medicine Faculty, Granada, Spain
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 200
  • Age - 40 Years to 70 Years   (Adult, Older Adult)
  • Outcome measures - Composite of cumulative death (i.e. mortality) for all causes and for specific causes.|Necessity of invasive assisted ventilation|Necessity of non-invasive assisted ventilation|Intensive care unit admission|Post-anesthesia care unit admission|Hospital admission|Medical consultation|Home care and isolation time|Bed rest time|symptoms' duration (i.e. cough, fever, nasal congestion, gastrointestinal symptoms, fatigue, anosmia, ageusia, diarrhea or alternative signs of COVID-19)|Subjective perception of recovery
NCT04738760 Clinical Outcomes of High Dose Vitamin D Versus Standard Dose in COVID-19 Egyptian Patients Recruiting Dec/01/2020 Jun/01/2021
  • Alternative id - COVID-VIT-D
  • Interventions -
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Teachers Hospital, Cairo, Please Select, Egypt
  • Study designs - Observational Model: Cohort|Time Perspective: Other
  • Enrollment - 150
  • Age - 18 Years to 65 Years   (Adult, Older Adult)
  • Outcome measures - Duration of hospitalization|In-hospital mortality|Clinical status improvement using six category ordinal scale|Change in gas exchange|Time to increase in oxygenation|Change in Lactate dehydrogenase (LDH) levels|Change in C-reactive protein (CRP) levels|Change in serum ferritin levels|Occurrence of secondary infection|Occurrence of at least one severe adverse event|Need for mechanical ventilator or intensive care unit (ICU) support
NCT04793243 Vitamin D3 Levels in COVID-19 Outpatients From Western Mexico Completed Not Applicable Aug/17/2020 Oct/24/2020
  • Alternative id - CI-07620
  • Interventions - Dietary Supplement: Vitamin D3
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Universidad de Guadalajara, Guadalajara, Jalisco, Mexico
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care
  • Enrollment - 42
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Baseline levels of serum vitamin D in COVID-19 patients|Correlation between D-dimer and vitamin D serum levels in COVID-19 patients|Correlation between transferrin and vitamin D serum levels in COVID-19 patients|Correlation between ferritin and vitamin D serum levels in COVID-19 patients|Effects of vitamin D3 supplementation on COVID-19 patients
NCT04386044 Investigating the Role of Vitamin D in the Morbidity of COVID-19 Patients Completed Jun/01/2020 Sep/08/2020
  • Alternative id - TGH1234
  • Interventions -
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Tameside Hospital NHS Foundation Trust, Ashton-under-Lyne, Greater Manchester, United Kingdom
  • Study designs - Observational Model: Other|Time Perspective: Other
  • Enrollment - 986
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - COVID-19 infection|Oxygen therapy for COVID-19|Discharge following COVID-19 hospitalisation|Death due to COVID-19
NCT04825093 Vitamin D Supplementarion in Pregnant Women at Risk and COVID-19 Not yet recruiting Not Applicable May/01/2021 Dec/30/2023
  • Alternative id - SVD-COVID-2020
  • Interventions - Dietary Supplement: Vitamin D supplementation in pregnant women
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Maria Jose Aguilar Cordero, Granada, Spain
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention
  • Enrollment - 500
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Serum concentration of 25-hydroxyvitamin D|Prevalence of preterm birth|Prevalence of preeclampsia|Prevalence of gestational diabetes mellitus|Prevalence of COVID-19|Severity of COVID-19|Miscarriage|Neonatal immunity|Birth Weight
NCT04385940 Vitamin D and COVID-19 Management Recruiting Phase 3 Mar/19/2021 Jan/01/2023
  • Alternative id - Pro00100606
  • Interventions - Dietary Supplement: Ddrops® products, 50,000 IU, Oral|Dietary Supplement: Vitamin D3
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - University of Alberta, Edmonton, Alberta, Canada
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 64
  • Age - 17 Years and older   (Child, Adult, Older Adult)
  • Outcome measures - Symptoms recovery|Hospitalization|Blood white blood cell count (WBC)|Duration of mechanical ventilation|Duration of hospitalization|Intensive care unit (ICU) admission|Duration of ICU stay|Blood C-reactive protein (CRP)|Blood Lymphocyte count|Blood Ferritin|Blood platelet count|Blood interleukin-6 (IL-6)|Blood Tumor Necrosis Factor alpha (TNF)
NCT05092698 The Efficacy of Vitamin D Supplementation in Patients With Severe and Extremely Severe COVID-19 Completed Not Applicable May/01/2020 Jan/31/2022
  • Alternative id - COVID-VIT
  • Interventions - Dietary Supplement: Vitamin D (cholecalciferol)|Dietary Supplement: Herbal oil
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Federal Research Clinical Center of Federal Medical & Biological Agency, Moscow, Russian Federation
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment
  • Enrollment - 110
  • Age - 18 Years to 100 Years   (Adult, Older Adult)
  • Outcome measures - Сomplete blood count|Сomplete blood count dynamics 1|Сomplete blood count dynamics 2|Сomplete blood count dynamics 3|C-reactive protein|C-reactive protein 1|C-reactive protein 2|C-reactive protein 3|Von Willebrand factor antigen|Thrombotic complications|Immunogram|Proinflammatory marker|Proinflammatory marker 1|Proinflammatory marker 2|Proinflammatory marker 3|inflammatory marker|inflammatory marker 1|inflammatory marker 2|inflammatory marker 3|Infection marker|Infection marker 1|Mortality|Mechanical ventilation duration|Non-invasive Mechanical ventilation duration|Length of stay in the ICU|Length of stay in the hospital|Infection complications
NCT04535791 Efficacy of Vitamin D Supplementation to Prevent the Risk of Acquiring COVID-19 in Healthcare Workers Completed Phase 3 Jul/15/2020 Jul/15/2021
  • Alternative id - R-2020-785-090
  • Interventions - Drug: Cholecalciferol
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Hospital Centro Medico Nacional Siglo XXI, Mexico City, Distrito Federal, Mexico
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
  • Enrollment - 321
  • Age - 18 Years to 70 Years   (Adult, Older Adult)
  • Outcome measures - Number of Participants with COVID-19|Number of Participants with hospitalization for COVID-19|Serum concentration of 25 (OH) vitamin D
NCT04733625 The Effect of Vitamin D Therapy on Morbidity and Moratlity in Patients With SARS-CoV 2 Infection Completed Not Applicable Sep/15/2020 Dec/17/2020
  • Alternative id - KA-2020/151
  • Interventions - Drug: Cholecalciferol|Drug: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Cairo university hospitals, Cairo, Egypt
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
  • Enrollment - 56
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Death or need for intubation
NCT04883203 The Effect of Vitamin D Supplementation on COVID-19 Recovery Completed Phase 3 Apr/22/2020 Oct/31/2020
  • Alternative id - VITD COVIDMonastir
  • Interventions - Drug: Vit-D 0.2 MG/ML Oral Solution [Calcidol]|Drug: Physiological Irrigating Solution
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Asma Sriha Belguit, Monastir, Tunisia
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment
  • Enrollment - 130
  • Age - 18 Years to 70 Years   (Adult, Older Adult)
  • Outcome measures - Vitamin D supplementation and recovery delay in COVID-19 patients
NCT04628000 Baseline Vitamin D Deficiency and COVID-19 Disease Severity Recruiting Oct/27/2020 Apr/14/2022
  • Alternative id - PIRB78
  • Interventions - Other: Vitamin D
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Parkview Medical Center, Pueblo, Colorado, United States
  • Study designs - Observational Model: Cohort|Time Perspective: Retrospective
  • Enrollment - 50
  • Age - 18 Years to 100 Years   (Adult, Older Adult)
  • Outcome measures - LOS duration in days|Supp O2 flow volume in L/min
NCT04487951 N-terminal Pro B-type Natriuretic Peptide and Vitamin D Levels as Prognostic Markers in COVID-19 Pneumonia Recruiting Jul/01/2020 Jan/01/2021
  • Alternative id - 2020-7-1
  • Interventions - Other: Pro BNP , Vitamin D
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Kasr Alainy Cairo University, Cairo, Giza, Egypt
  • Study designs - Observational Model: Case-Control|Time Perspective: Cross-Sectional
  • Enrollment - 100
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - NT-pro-BNP and Vitamin D|Assessment of any possible correlation between NT-pro-BNP and Vitamin D and the need for mechanical ventilation or mortality in COVID-19 infection
NCT04394390 Do Vitamin D Levels Really Correlated With Disease Severity in COVID-19 Patients? Enrolling by invitation May/01/2020 Jun/30/2020
  • Alternative id - 1
  • Interventions - Dietary Supplement: vitamin d
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Bursa City Hospital, Bursa, Dogankoy, Turkey
  • Study designs - Observational Model: Case-Control|Time Perspective: Prospective
  • Enrollment - 100
  • Age - Child, Adult, Older Adult
  • Outcome measures - laboratory measured vitamin D levels
NCT04403932 Increased Risk of Severe Coronavirus Disease 2019 in Patients With Vitamin D Deficiency Completed Apr/17/2020 Aug/01/2020
  • Alternative id - 20/428-E_COVID
  • Interventions -
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Hospital Clínico San Carlos, Madrid, Spain
  • Study designs - Observational Model: Cohort|Time Perspective: Prospective
  • Enrollment - 300
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - severe COVID-19
NCT04476745 The Effect of D3 on Selected Cytokines Involved in Cytokine Storm in the Covid-19 Uninfected Jordanian People Completed Not Applicable Oct/05/2020 Apr/15/2021
  • Alternative id - 2020-PHA-16
  • Interventions - Dietary Supplement: Vitamin D3
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Mahmoud S Abu-Samak, Amman, Jordan
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention
  • Enrollment - 100
  • Age - 30 Years to 66 Years   (Adult, Older Adult)
  • Outcome measures - IL-1 beta|IL-6|TNF|serum concentrations of 25-hydroxyvitamin D
NCT04502667 Efficacy of Vitamin D Treatment in Pediatric Patients Hospitalized by COVID-19 Recruiting Phase 3 Jul/15/2020 Apr/01/2021
  • Alternative id - R-2020-3603-020
  • Interventions - Drug: Cholecalciferol
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Hospital Centro Medico Nacional Siglo XXI, Mexico City, Distrito Federal, Mexico
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 40
  • Age - 1 Month to 17 Years   (Child)
  • Outcome measures - INTERLEUKINS (IL-2,6,7,10) (pg/ml)|FERRITIN (ng/ml)|DIMER-D|Vitamin D (ng/ml)
NCT04459247 Short Term, High Dose Vitamin D Supplementation for COVID-19 Completed Not Applicable Jun/15/2020 Apr/10/2021
  • Alternative id - 121/20
  • Interventions - Drug: Vit D
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Deptt of Endocrinology, Chandigarh, India
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment
  • Enrollment - 40
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Virus negativity|Inflammatory Marker|Inflammatory Marker 2
NCT03188796 The VITDALIZE Study: Effect of High-dose Vitamin D3 on 28-day Mortality in Adult Critically Ill Patients Recruiting Phase 3 Oct/10/2017 Feb/01/2023
  • Alternative id - VITDALIZE 1.0
  • Interventions - Drug: Cholecalciferol|Drug: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - LKH Hochsteiermark Standort Bruck, Bruck An Der Mur, Austria|LKH Enzenbach, Enzenbach, Austria|LKH Feldbach, Feldbach, Austria|LKH Fürstenfeld, Fürstenfeld, Austria|Medical University of Graz, Graz, Austria|Medical University Innsbruck, Innsbruck, Austria|Klinikum am Wörthersee, Klagenfurt, Austria|LKH Hochsteiermark Standort Leoben, Leoben, Austria|Barmherzige Brüder Konventhospital Linz, Linz, Austria|Barmherzige Schwestern, Linz, Austria|Kepler Universitätsklinikum Linz, Linz, Austria|Krankenhaus Schwarzach, Schwarzach Im Pongau, Austria|Barmherzige Brüder, Vienna, Austria|Medical University of Vienna, Vienna, Austria|LKH Villach, Villach, Austria|Kaiser Franz Josef Spital Wien, Wien, Austria|Erasme Hospital, Brussel, Belgium|CHU de Charleroi, Charleroi, Belgium|CHR Citadelle, Liège, Belgium|CHU Ambroise Pare, Mons, Belgium
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
  • Enrollment - 2400
  • Age - 18 Years to 100 Years   (Adult, Older Adult)
  • Outcome measures - 28-day mortality|Hospital Length of stay|Hypercalcemia at day 5|Hospital readmissions
NCT04363840 The LEAD COVID-19 Trial: Low-risk, Early Aspirin and Vitamin D to Reduce COVID-19 Hospitalizations Withdrawn Phase 2 May/01/2020 Dec/01/2020
  • Alternative id - 20-063
  • Interventions - Drug: Aspirin 81 mg|Dietary Supplement: Vitamin D
  • Study type - Interventional
  • Study results - No Results Available
  • Locations -
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 0
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Hospitalization
NCT05166005 Severity of COVID-19 and Vitamin D Supplementation Active, not recruiting Phase 4 Apr/01/2020 Dec/01/2022
  • Alternative id - VitaD-COVID
  • Interventions - Drug: vitamin D
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Almazov National Medical Research Centre, of the Ministry of Health of the Russian Federation, Saint Petersburg, Russian Federation
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 350
  • Age - 18 Years to 75 Years   (Adult, Older Adult)
  • Outcome measures - Combined: severity, ICU hospitalization, outcome of the disease on 14-21 days|Serum 25(OH)D level|Serum APPs (acute phase proteins) levels, cytokine/chemokine concentrations|Duration of hospitalization|Interleukin-6 inhibitors application
NCT04407286 Vitamin D Testing and Treatment for COVID 19 Completed Phase 1 May/19/2020 Nov/30/2020
  • Alternative id - STUDY00011960
  • Interventions - Dietary Supplement: Vitamin D3
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Arizona State University, Tempe, Arizona, United States
  • Study designs - Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 41
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Vitamin D levels|severity of COVID 19 symptoms
NCT04709744 Impact of Vitamin D Level and Supplement on SLE Patients During COVID-19 Pandemic Completed Apr/01/2020 Dec/30/2020
  • Alternative id - RP.21.01.91
  • Interventions - Drug: Vitamin D|Diagnostic Test: ELISA
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Mansoura University Hospital, Mansoura, DK, Egypt
  • Study designs - Observational Model: Case-Only|Time Perspective: Prospective
  • Enrollment - 38
  • Age - 18 Years to 80 Years   (Adult, Older Adult)
  • Outcome measures - Level of serum vitamin D in SLE infected with COVID-19|Vitamin D level with COVID-19 severity
NCT04399746 Ivermectin-Azithromycin-Cholecalciferol (IvAzCol) Combination Therapy for COVID-19 Completed Not Applicable Mar/15/2020 Jun/10/2020
  • Alternative id - IvAzCol
  • Interventions - Drug: Ivermectin|Drug: Azithromycin|Drug: Cholecalciferol
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Outpatient treatment, Mexico City, Mexico
  • Study designs - Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 30
  • Age - 18 Years to 90 Years   (Adult, Older Adult)
  • Outcome measures - Viral clearance|Symptoms duration|SpO2|SpO2/FiO2
NCT04335084 A Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection Recruiting Phase 2 Jun/22/2020 Jul/01/2025
  • Alternative id - PRG-042
  • Interventions - Drug: Hydroxychloroquine|Dietary Supplement: Vitamin C|Dietary Supplement: Vitamin D|Dietary Supplement: Zinc
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - ProgenaBiome, Ventura, California, United States
  • Study designs - Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention
  • Enrollment - 600
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Prevention of COVID-19 symptoms as recorded in a daily diary|Safety as determined by presence or absence of Adverse Events and Serious Adverse Events
NCT04952857 Short Term, High Dose Vitamin D Supplementation in Moderate to Severe COVID-19 Disease Completed Phase 4 Aug/01/2021 Dec/10/2021
  • Alternative id - INT/2020/001068
  • Interventions - Drug: cholecalciferol 6 lakh IU
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Deptt of Endocrinology, Chandigarh, India
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment
  • Enrollment - 90
  • Age - 18 Years to 80 Years   (Adult, Older Adult)
  • Outcome measures - Sequential Organ Failure Assessment (SOFA)|Sequential Organ Failure Assessment (SOFA) Score|Sequential Organ Failure Assessment (SOFA) score
NCT04482686 Trial of Combination Therapy to Treat COVID-19 Infection Active, not recruiting Phase 1 Dec/09/2020 Jul/01/2022
  • Alternative id - PRG-049
  • Interventions - Drug: Ivermectin|Drug: Doxycycline Hcl|Dietary Supplement: Zinc|Dietary Supplement: Vitamin D3|Dietary Supplement: Vitamin C
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - ProgenaBiome, Ventura, California, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment
  • Enrollment - 31
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Time to Non-Infectivity by RT-PCR|Time to Symptom progression in days as measured by NEWS scoring system (National Early Warning Score)|Time to Symptom improvement as measured by NEWS scoring system (National Early Warning Score)|Efficacy of Treatment as measured by Titer|Efficacy of Treatment as measured by RT-PCR|Safety of Treatment as Measured by D-Dimer|Safety of Treatment as Measured by Pro-Calcitonin|Safety of Treatment as Measured by C-Reactive Protein|Safety of Treatment as Measured by Ferritin|Safety of Treatment as Measured by Liver Enzymes|Safety of Treatment as Measured by Complete Blood Count|Safety of Treatment as Measured by Electrolyte Levels|Safety of Treatment as Measured by Treatment Related Adverse Events
NCT04435119 Covid-19 and Vitamin D in Nursing-home Completed Mar/15/2020 May/15/2020
  • Alternative id - 2020/67
  • Interventions -
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Angers University Hospital, Angers, France
  • Study designs - Observational Model: Cohort|Time Perspective: Retrospective
  • Enrollment - 96
  • Age - 70 Years and older   (Older Adult)
  • Outcome measures - Number of deaths of any cause in nursing-home residents with SARS-CoV-2 infection, depending on the use of bolus vitamin D3 supplementation during or just before COVID-19|Clinical severity score of COVID19 in nursing-home residents with SARS-CoV-2 infection, depending on the use of bolus vitamin D3 supplementation during or just before COVID-19
NCT05008003 Study to Investigate Treatment Benefits of Combination of Vit D3, Quercetin and Curcumin for Early Mild Symptoms of COVID-19 Recruiting Not Applicable Aug/06/2021 Mar/31/2022
  • Alternative id - CQC/COVID/08-2021
  • Interventions - Drug: Standard of care|Dietary Supplement: Combination of oral quercetin, curcumin and vitamin D3
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Ayub Teaching Hospital, Abbottabad, Khyber Pakhtunkhwa, Pakistan
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 50
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - SARS-CoV-2 Negativity by RT-PCR|COVID-19 symptoms improvement|Changes in CRP level|Changes in D-dimer level|Changes in LDH level|Changes in ferritin level|Changes in full blood count
NCT04949412 Assessment of Vitamin D Level in COVID-19 Completed Jun/11/2021 Sep/25/2021
  • Alternative id - Soh-Med-21-06-30
  • Interventions - Diagnostic Test: Vitamin D
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Mona Mohammed Abdelrahman, Sohag, Egypt
  • Study designs - Observational Model: Cohort|Time Perspective: Prospective
  • Enrollment - 98
  • Age - Child, Adult, Older Adult
  • Outcome measures - serum level of vitamin D in patients who infected with COVID19
NCT04489628 Tele-health Enabled Clinical Trial for COVID-19 Withdrawn Phase 1|Phase 2 Aug/01/2020 Jun/01/2021
  • Alternative id - STUDY20200461
  • Interventions - Drug: Vitamin D3 or Placebo|Device: Doctella telehealth monitoring
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Northwestern University, Chicago, Illinois, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
  • Enrollment - 0
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Patients requiring admission to the hospital or experiencing death
NCT04621058 Efficacy of Vitamin D Treatment in Mortality Reduction Due to COVID-19. Recruiting Phase 3 Nov/09/2020 Nov/30/2021
  • Alternative id - VITD
  • Interventions - Drug: Vitamin D|Drug: PLACEBO
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Joaquín Durán Cantolla, Vitoria-Gasteiz, Alava, Spain
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 108
  • Age - Child, Adult, Older Adult
  • Outcome measures - MORTALITY|Intensive care admissions|Length of hospital stay|Prevalence of vitamin D deficiency|Incremental cost effectiveness ratio (ICER)
NCT04372017 Hydroxychloroquine as Post-Exposure Prophylaxis Against COVID-19 Infection Terminated Phase 3 May/14/2020 Jun/04/2021
  • Alternative id - PEPCOH
  • Interventions - Drug: Hydroxychloroquine|Dietary Supplement: Vitamin D
  • Study type - Interventional
  • Study results - Has Results
  • Locations - Sanford Health, Sioux Falls, South Dakota, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention
  • Enrollment - 1
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Cohort A: Percentage of COVID-19 Exposed Healthcare Workers Treated With Hydroxychloroquine With a Positive COVID-19 Test.|Cohort B: Percentage of COVID-19 Exposed High-risk Individuals Treated With Hydroxychloroquine With a Positive COVID-19 Test.
NCT05077813 Utilizing the Crosstalk Among Chicoric Acid, 13-Cis Retinoic Acid(Aerosolized), Minocycline and Vitamin D as a Potent Quadrate Therapy for Treating Patients With Multidrug-resistant TB and Patient With Both Multidrug-resistant TB and COVID-19 Not yet recruiting Phase 2 Dec/01/2021 Feb/01/2022
  • Alternative id - How to kill Tuberculosis
  • Interventions - Combination Product: 13 cis retinoic acid, Minocycline, Chicroic Acid and Vitamin D for (MDR-TB)|Combination Product: 9 cis retinoic acid, Minocycline, Chicroic Acid and Vitamin D for (MDR-TB)|Combination Product: All trans retinoic acid , Minocycline,Chicroic Acid and Vitamin D for (MDR-TB)|Combination Product: All trans retinoic acid, Minocycline, Chicroic Acid and Vitamin D For (COVID-19 and MDR-TB)|Combination Product: 13 cis retinoic acid, Minocycline, Chicroic Acid and Vitamin D For (COVID-19 and MDR-TB)|Other: The standard therapy
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Kafr El-sheikh University, Cairo, Kafr El-sheikh, Egypt|Ministry of health. First health cluster, Riyadh, Riaydh, Saudi Arabia
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment
  • Enrollment - 250
  • Age - 18 Years to 65 Years   (Adult, Older Adult)
  • Outcome measures - Time to first negative SARS-CoV-2 PCR in NP swap and Mycobacterium tuberculosis sputum culture|Sputum culture result (positive or negative)& COVID-19 PCR (positive or negative)|Serum levels of CRP and ESR|All cause mortality rate|Absolute lymphocyte counts (CD4,CD8 and CD25+FOXP3+ Regulatory T)|Measurement of cytokine (IFN-gamma and alpha , IL-6, IL-10, TNF-alpha, TGF-beta) levels produced in response to M. tb.|Vitamin D status|Retinoic acid status|Minocycline status|Serum indoleamine 2,3-dioxygenase (IDO) enzyme status|Chicoric Acid status
NCT04344041 COvid-19 and Vitamin D Supplementation: a Multicenter Randomized Controlled Trial of High Dose Versus Standard Dose Vitamin D3 in High-risk COVID-19 Patients (CoVitTrial) Completed Phase 3 Apr/15/2020 Jan/14/2021
  • Alternative id - 2020-001602-34
  • Interventions - Drug: cholecalciferol 200,000 IU|Drug: cholecalciferol 50,000 IU
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - CHU Angers, Angers, France|CHU Bordeaux, Bordeaux, France|CH Le Mans, Le Mans, France|CHU Limoges, Limoges, France|CHU Nantes, Nantes, France|CHU Nice, Nice, France|CHU Saint Etienne, Saint Etienne, France|CH Saumur, Saumur, France|CHU Tours, Tours, France
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 260
  • Age - 65 Years and older   (Older Adult)
  • Outcome measures - Number of death of any cause, during the 14 days following the inclusion and intervention.|Number of death of any cause, during the 28 days following the inclusion and intervention.|Clinical evolution between day 0 and day 14 based on the change of the WHO Ordinal Scale for Clinical Improvement (OSCI) for COVID-19|Clinical evolution between day 0 and day 28 based on the change of the OSCI for COVID-19|Rate of patients with at least one severe adverse event at day 28, according to the regulations|Number of death of any cause during the 14 days following the inclusion and intervention, in patients with severe hypovitaminosis D (25-OHD <25nmol/L) at baseline|Number of death of any cause during the 28 days following the inclusion and intervention, in patients with severe hypovitaminosis D (25-OHD <25nmol/L) at baseline|Clinical evolution between day 0 and day 14 based on the change of the OSCI for COVID-19, in patients with severe hypovitaminosis D (25-OHD <25nmol/L) at baseline|Clinical evolution between day 0 and day 28 based on the change of the OSCI for COVID-19, in patients with severe hypovitaminosis D (25-OHD<25nmol/L) at baseline|Number of death of any cause during the 14 days following the inclusion and intervention, depending on serum vitamin D concentration achieved at day 7 (25-OHD<75nmol/L or 25-OHD≥75nmol/L)|Number of death of any cause during the 28 days following the inclusion and intervention, depending on serum vitamin D concentration achieved at day 7 (25-OHD<75nmol/L or 25-OHD≥75nmol/L)|Clinical evolution between day 0 and day 14 based on the change of the OSCI for COVID-19, depending on serum vitamin D concentration achieved at day 7 (25-OHD<75nmol/L or 25-OHD≥75nmol/L)|Clinical evolution between day 0 and day 28 based on the change of the OSCI for COVID-19, depending on serum vitamin D concentration achieved at day 7 (25-OHD<75nmol/L or 25-OHD≥75nmol/L)|Number of death of any cause during the 14 days following the inclusion and intervention, in patients with severe hypovitaminosis D (25-OHD<25nmol/L) at day 0, depending on serum vitamin D concentration achieved at day 7 (<75nmol/L or ≥75nmol/L)|Number of death of any cause during the 28 days following the inclusion and intervention, in patients with severe hypovitaminosis D (25-OHD<25nmol/L) at day 0, depending on serum vitamin D concentration achieved at day 7 (<75nmol/L or ≥75nmol/L)|Clinical evolution between day 0 and day 14 based on the change of the OSCI for COVID-19, in patients with severe hypovitaminosis D (25-OHD<25nmol/L) at day 0, depending on serum vitamin D concentration achieved at day 7 (<75nmol/L or ≥75nmol/L)|Clinical evolution between day 0 and day 28 based on the change of the OSCI for COVID-19, in patients with severe hypovitaminosis D (25-OHD<25nmol/L) at day 0, depending on serum vitamin D concentration achieved at day 7 (<75nmol/L or ≥75nmol/L)|Number of death of any cause during the 14 days following the inclusion and intervention, depending on evolution of serum vitamin D concentration between day 0 and day 7|Number of death of any cause during the 28 days following the inclusion and intervention, depending on evolution of serum vitamin D concentration between day 0 and day 7|Clinical evolution between day 0 and day 14 based on the change of the OSCI for COVID-19, depending on evolution of serum vitamin D concentration between day 0 and day 7|Clinical evolution between day 0 and day 28 based on the change of the OSCI for COVID-19, depending on evolution of serum vitamin D concentration between day 0 and day 7|Number of death of any cause during the 14 days following the inclusion and intervention, compared to mortality data in French hospital geriatric units from the current national survey by the French Society of Geriatrics and Gerontology
NCT04596657 Vitamin D3 Supplementation to Prevent Respiratory Tract Infections Active, not recruiting Not Applicable Oct/27/2020 Sep/30/2022
  • Alternative id - 20-455
  • Interventions - Dietary Supplement: Vitamin D supplementation
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Cooper University Hospital, Camden, New Jersey, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention
  • Enrollment - 876
  • Age - 52 Years and older   (Adult, Older Adult)
  • Outcome measures - Respiratory tract infection
NCT04400890 Randomized Proof-of-Concept Trial to Evaluate the Safety and Explore the Effectiveness of Resveratrol, a Plant Polyphenol, for COVID-19 Terminated Phase 2 Sep/12/2020 Mar/01/2021
  • Alternative id - McCreary2020
  • Interventions - Drug: Resveratrol|Dietary Supplement: Vitamin D3
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Mt Carmel HealthSystems, Columbus, Ohio, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 100
  • Age - 45 Years and older   (Adult, Older Adult)
  • Outcome measures - Hospitalization rates for COVID-19|ICU Admission Rates|Invasive Ventilation Rates|Pneumonia
NCT04641195 Vitamin D and Zinc Supplementation for Improving Treatment Outcomes Among COVID-19 Patients in India Recruiting Phase 3 Apr/22/2021 Sep/30/2022
  • Alternative id - VR3- 172649
  • Interventions - Dietary Supplement: Vitamin D3 (cholecalciferol)|Dietary Supplement: Zinc (zinc gluconate)|Dietary Supplement: Zinc (zinc gluconate) & Vitamin D (cholecalciferol)|Other: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Saifee Hospital, Mumbai, Maharashtra, India|King Edward Memorial (KEM) Hospital, Pune, Maharashtra, India
  • Study designs - Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 700
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Time to recovery|All-cause mortality|Necessity for assisted ventilation|Individual symptoms duration|Vitamin D|Zinc|Interleukin 6 (IL-6)|Angiopoietin-2|sTREM-1|Immunoglobulin M (IgM)|Immunoglobulin (IgG)|Duration of hospital stay
NCT04407572 Evaluation of the Relationship Between Zinc Vitamin D and b12 Levels in the Covid-19 Positive Pregnant Women Completed Apr/20/2020 Jun/14/2020
  • Alternative id - zinc-dvit-covid19
  • Interventions - Other: Serum zinc, vitamin d vitamin b12 levels .
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Pinar Yalcin Bahat, Istanbul, İ̇stanbul, Turkey
  • Study designs - Observational Model: Case-Control|Time Perspective: Prospective
  • Enrollment - 44
  • Age - 18 Years to 45 Years   (Adult)
  • Outcome measures - Serum zinc, vitamin d vitamin b12 deficiency levels
NCT04552951 Effect of Vitamin D on Morbidity and Mortality of the COVID-19 Recruiting Phase 4 Apr/04/2020 Dec/30/2020
  • Alternative id - 2020-019-PF-CAANJ
  • Interventions - Drug: Cholecalciferol
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 80
  • Age - Child, Adult, Older Adult
  • Outcome measures - Mortality|Admission to Intensive Care Unit (ICU)|Time of hospitalization|Clinical changes|Radiological changes|Calcidiol changes|Inflammation markers changes (CRP)|Inflammation markers changes (IL-6)|Inflammation markers changes (Leucocytes)|Inflammation markers changes (D-dimer)|General biochemical parameters changes (Creatinine)|General biochemical parameters changes (Ferritin)|General biochemical parameters changes (Bilirubin)|General biochemical parameters changes (Albumin)|General biochemical parameters changes (Haemoglobin)|General biochemical parameters changes (HDL cholesterol)|General biochemical parameters changes (Procalcitonin)|General biochemical parameters changes (Protonin)|General biochemical parameters changes (Calcium)|General biochemical parameters changes (Phosphate)|General biochemical parameters changes (pO2)
NCT04449718 Vitamin D Supplementation in Patients With COVID-19 Completed Not Applicable Jun/01/2020 Oct/07/2020
  • Alternative id - 30959620.4.0000.0068
  • Interventions - Dietary Supplement: Vitamin D|Dietary Supplement: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Clinical Hospital of the School of Medicine, University of Sao Paulo, Sao Paulo, Brazil
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 240
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Length of hospitalization|Mortality|Number of cases admitted to Intensive Care Unit (ICU)|Length of use of mechanic ventilator|Number and severity of symptoms|Inflammatory markers|C-reactive protein|Vitamin D|Creatinine|Calcium|Physical activity
NCT04483635 PRevention of COVID-19 With Oral Vitamin D Supplemental Therapy in Essential healthCare Teams Terminated Phase 3 Feb/08/2021 May/25/2021
  • Alternative id - MP-21-2021-3044
  • Interventions - Dietary Supplement: Placebo|Dietary Supplement: Vitamin D
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - CHUM, Montreal, Quebec, Canada|CHU Sainte-Justine (CHUSJ), Montreal, Quebec, Canada
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  • Enrollment - 34
  • Age - 18 Years to 69 Years   (Adult, Older Adult)
  • Outcome measures - Change in incidence of laboratory-confirmed COVID-19 infection|Distribution of disease severity|Duration of symptoms in COVID-19 positive participants|Number of participants with COVID-19 positive IgG serology|Number of workday absences due to COVID-19 suspected/confirmed infection|Number of workday absences for any reason|Adverse health events
NCT05269017 Vitamin D Nasal Drops in Post COVID Parosmia Not yet recruiting Phase 2 Apr/01/2022 Dec/01/2022
  • Alternative id - 1/2022 PHAR2
  • Interventions - Drug: Vitamin D3|Drug: Budesonide nasal spray
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Menoufia Faculty of Medicine, Shibīn Al Kawm, Menoufia, Egypt
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 60
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Comparison between the pre and post treatment values|Comparison between case and control groups regarding the post treatment results|Assessment of the side effects of Ivermectin nasal drops
NCT05037253 COVID-19 Morbidity in Healthcare Workers and Vitamin D Supplementation Completed Phase 4 Oct/30/2020 May/30/2021
  • Alternative id - 0811-20-01C
  • Interventions - Drug: Vitamin D
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health of the Russian Federation, Saint Petersburg, Russian Federation
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 128
  • Age - 18 Years to 65 Years   (Adult, Older Adult)
  • Outcome measures - SARS-CoV-2 antibodies (IgG)|Positive PCR test|Serum 25(OH)D level|COVID-19 clinical features|CT data
NCT05126602 Vitamin D Supplementation and Clinical Improvement in COVID-19 Completed Not Applicable Apr/01/2021 Nov/01/2021
  • Alternative id - 0411212204
  • Interventions - Dietary Supplement: Vitamin D3 10000 IU|Dietary Supplement: Vitamin D3 1000 IU
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Wahidin Sudirohusodo General Hospital, Makassar, South Sulawesi, Indonesia
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 60
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Clinical Recovery Time|Length of Stay|PCR Conversion time|Platelet to Lymphocyte Ratio / PLR in blood|Total Lymphocyte Count (TLC) in blood|Neutrophil-Lymphocyte Ratio (NLR) in blood|D-Dimer
NCT04411446 Cholecalciferol to Improve the Outcomes of COVID-19 Patients Completed Phase 4 Aug/11/2020 Jul/28/2021
  • Alternative id - 001
  • Interventions - Drug: Vitamin D|Drug: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Hospital de Alta Complejidad en Red El Cruce, Florencio Varela, Buenos Aires, Argentina
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 218
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Respiratory SOFA.|Need of a high dose of oxygen or mechanical ventilation.|Change in oxygen saturation.|Oxygen desaturation.|Change in Quick SOFA score.|Myocardial infarction.|Stroke.|Acute kidney injury.|Pulmonary thromboembolism.|Combined endpoint (stroke, myocardial infarction, acute kidney injury and pulmonary thromboembolism.|Admission to ICU.|Invasive Mechanical Ventilation.|Hospital Length of Stay.|ICU length of stay.|Death
NCT04386850 Oral 25-hydroxyvitamin D3 and COVID-19 Recruiting Phase 2|Phase 3 Apr/14/2020 Mar/15/2021
  • Alternative id - IRCT2020-0401046909N2|IRCT20200401046909N1
  • Interventions - Drug: Oral 25-Hydroxyvitamin D3
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Tehran University of Medical Sciences, Tehran, Iran, Islamic Republic of
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  • Enrollment - 1500
  • Age - 18 Years to 75 Years   (Adult, Older Adult)
  • Outcome measures - COVID-19 (SARA-Cov-2) infection|Severity of COVID-19 (SARA-Cov-2) infection|Hospitalization|Disease duration|Death|Oxygen support|Type of oxygen support|Symptoms of COVID-19|Serum Levels of 25-hydroxyvitamin D3|Serum levels of calcium|Serum levels of phosphorus|Serum levels of creatinine|Serum levels of albumin|Serum levels of the blood urea nitrogen (BUN)|Serum levels of the parathyroid hormone (PTH)
NCT05002530 Investigating the Potential Role of Aerosolized Retinoic Acid, a Potent Vitamin A Metabolite for Treating COVID-19 Anosmia and Retinoic Acid Insufficiency .A Novel Approach for Regaining Sense of Smell. Not yet recruiting Phase 4 Nov/01/2021 Jan/01/2022
  • Alternative id - Vitamin A and Anosmnia
  • Interventions - Drug: Aerosolized 13 cis retinoic acid plus Vitamin D|Drug: Aerosolized All trans retinoic acid plus Vitamin D|Other: Standard therapy
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Quan Liu, Foshan, Guangdong, China|Tamer Haydara, Kafr Ash Shaykh, Kafr Elshiekh, Egypt|Ministry of health.First health cluster ,Riaydh, Riyadh, Saudi Arabia
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 10000
  • Age - 18 Years to 70 Years   (Adult, Older Adult)
  • Outcome measures - Improvement of olfaction|Modified Brief Questionnaire of Olfactory Dysfunction (mQOD-NS)|Sinonasal Outcomes Test|Sinonasal Outcomes Test (SNOT-22)|Frequency of adverse events and severe adverse events|Angiotensin-converting enzyme II (ACE2) expression in lungs and olfactory region|STRA6 expression in lungs and olfactory region|Retinoic acid blood levels|Il-6 blood levels
NCT04579640 Trial of Vitamin D to Reduce Risk and Severity of COVID-19 and Other Acute Respiratory Infections Active, not recruiting Phase 3 Oct/27/2020 Feb/28/2022
  • Alternative id - 289515
  • Interventions - Dietary Supplement: Vitamin D
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Queen Mary University of London, London, County (optional), United Kingdom
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention
  • Enrollment - 6200
  • Age - 16 Years and older   (Child, Adult, Older Adult)
  • Outcome measures - Proportion of participants experiencing at least one doctor-diagnosed or laboratory-confirmed acute respiratory infection of any cause.|Proportion of participants developing PCR- or antigen test-positive COVID-19|Proportion of participants who are prescribed one or more courses of antibiotic treatment for acute respiratory infection|Proportion of participants with asthma who experience one or more exacerbations of asthma requiring treatment with oral corticosteroids and/or requiring hospital treatment|Proportion of participants with COPD who experience one or more exacerbations of COPD requiring treatment with oral corticosteroids and/or antibiotics, and/or requiring hospital treatment|Proportion of participants who have had PCR-, antigen test- or antibody test-confirmed SARS-CoV-2 infection who report symptoms of COVID-19 lasting more than 4 weeks after onset|Mean MRC dyspnoea score at the end of the study in people who have had PCR-, antigen test- or antibody test-confirmed SARS-CoV-2 infection and who report symptoms of COVID-19 lasting more than 4 weeks after onset|Mean FACIT Fatigue Scale score at the end of the study in people with antigen test- or antibody test-confirmed SARS-CoV-2 infection and who report symptoms of COVID-19 lasting more than 4 weeks after onset|Mean COVID-19 Recovery Questionnaire score at the end of the study in people who have had antigen test- or antibody test-confirmed SARS-CoV-2 infection and who report symptoms of COVID-19 lasting more than 4 weeks after onset|Proportion of participants who experience one or more acute respiratory infections requiring hospitalisation|Proportion of participants who experience COVID-19 requiring hospitalisation|Proportion of participants hospitalised for COVID-19 requiring ventilatory support|Proportion of participants dying of any cause during participation in the trial|Proportion of participants dying of acute respiratory infection during participation in the trial|Proportion of participants dying of COVID-19 during participation in the trial|Mean end-study 25(OH)D concentration (sub-set of participants having end-study tests of vitamin D status)|Proportion of participants experiencing known hypercalcaemia|Proportion of participants experiencing a probable or definite adverse reaction to vitamin D supplementation|Proportion of participants experiencing a serious adverse event of any cause|Proportion of SARS-CoV-2 vaccinated participants with antibodies to SARS-CoV-2 spike protein|Median titre of antibodies to SARS-CoV-2 spike protein in SARS-CoV-2 vaccinated participants|Proportion of SARS-CoV-2 vaccinated participants with antigen-specific T cell responses to SARS-CoV-2 spike protein (sub-set of participants)|Frequency of antigen-specific T cells reacting to SARS-CoV-2 spike protein in SARS-CoV-2 vaccinated participants (sub-set of participants)
NCT04828538 Vitamin D, Omega-3, and Combination Vitamins B, C and Zinc Supplementation for the Treatment and Prevention of COVID-19 Active, not recruiting Not Applicable Jan/01/2021 Nov/30/2021
  • Alternative id - MCI102020
  • Interventions - Dietary Supplement: Vitamin D|Dietary Supplement: Omega DHA / EPA|Dietary Supplement: Vitamin C, Vitamin B complex and Zinc Acetate|Other: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Hospital de Soledad, San Luis Potosí, SLP, Mexico
  • Study designs - Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Other
  • Enrollment - 1800
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Covid infection rate (PREVENT Trial only)|Incidence of severe outcome (TREAT Trial only)|Incidence of hospitalization and death (PREVENT Trial only)|Length of hospitalization and death after discharge (TREAT Trial only)
NCT05221983 COVID-19 and Vitamin D: Length of Hospital Stay and Mortality Completed Aug/21/2021 Nov/16/2021
  • Alternative id - YuksekIU-SCOZBEK001
  • Interventions -
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Republic of Turkey Ministry of Health Ankara City Hospitals Neurology-Orthopedics Hospital, Ankara, Turkey
  • Study designs - Observational Model: Case-Only|Time Perspective: Retrospective
  • Enrollment - 168
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Level of Vitamin D|Relationship between vitamin D level and mortality|Relationship between vitamin D level and hospital stay|Effects of additional diseases (Diabetes mellitus, hypertension, etc.) on hospital stay and mortality
NCT04395768 International ALLIANCE Study of Therapies to Prevent Progression of COVID-19 Recruiting Phase 2 Sep/09/2020 Dec/31/2021
  • Alternative id - Alliance-COVID19
  • Interventions - Dietary Supplement: Vitamin C|Drug: Hydroxychloroquine|Drug: Azithromycin|Dietary Supplement: Zinc Citrate|Dietary Supplement: Vitamin D3|Dietary Supplement: Vitamin B12
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - National Institute of Integrative Medicine, Melbourne, Victoria, Australia
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 200
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Symptoms|Length of hospital stay|invasive mechanical ventilation or mortality|Mortality|mechanical ventilation|oxygen|ICU|days in hospital|days in ICU|renal replacement therapy|Extracorporeal support
NCT04780061 Dietary Supplements for COVID-19 Recruiting Phase 3 Jul/12/2021 Dec/01/2022
  • Alternative id - 20210072-01H
  • Interventions - Drug: Vitamin D3 50,000 IU|Dietary Supplement: Vitamin C/Zinc|Dietary Supplement: Vitamin K2/D|Other: Microcrystalline Cellulose Capsule|Other: Medium Chain Triglyceride Oil
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - The Centre for Health Innovation, Ottawa, Ontario, Canada
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 200
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Participant-reported overall health|Effect of COVID-19 on the health status of participants|Symptom Severity of common COVID-19 symptoms|Total symptom duration|Incidence of delayed return to usual health|Frequency of Hospitalizations|Hospital Length of Stay|All-cause mortality
NCT04351490 Impact of Zinc and Vitamin D3 Supplementation on the Survival of Aged Patients Infected With COVID-19 Withdrawn Not Applicable Apr/01/2020 Jul/01/2020
  • Alternative id - 2020_30|2020-A00873-36
  • Interventions - Dietary Supplement: Zinc gluconate|Dietary Supplement: 25-OH cholecalciferol
  • Study type - Interventional
  • Study results - No Results Available
  • Locations -
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 0
  • Age - 60 Years and older   (Adult, Older Adult)
  • Outcome measures - Survival rate in asymptomatic subjects at inclusion|Survival rate in symptomatic subjects at inclusion|Survival rate in overall subjects|Cumulative incidence of Covid-19 infection in asymptomatic subjects at inclusion
NCT04476680 Influence of Military Preventive Policy for reCruit Training on COVID-19 Seroconversion Recruiting Not Applicable Sep/01/2020 Apr/28/2021
  • Alternative id - 1070MODREC20
  • Interventions - Dietary Supplement: Vitamin D
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Headingley and City campuses, Leeds Beckett University, Leeds, Yorkshire, United Kingdom|Infantry Training Centre Catterick, Catterick Garrison, United Kingdom
  • Study designs - Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention
  • Enrollment - 900
  • Age - 18 Years to 30 Years   (Adult)
  • Outcome measures - Seroconversion|Interim analysis - seropositivity at 12 weeks|Dried Blood Spot performance|Salivary IgA performance|Prevalence of SARS-CoV-2|Change in seropositivity|Change in seroconversion rate
NCT04370808 VITACOV: Vitamin D Polymorphisms and Severity of COVID-19 Infection Completed Aug/01/2020 Jan/31/2021
  • Alternative id - VITACOV
  • Interventions - Other: Exposure
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Cardiovascular Center at Universidade de Lisboa, Lisbon, Lisboa, Portugal|Centro Hospitalar Universitário Lisboa Norte, Lisbon, Lisboa, Portugal|Centro Hospitalar de São João, Oporto, Portugal
  • Study designs - Observational Model: Case-Only|Time Perspective: Prospective
  • Enrollment - 517
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Differences in vitamin D blood levels between COVID-19 patients with different degrees of disease severity.|Differences in genetic variants in vitamin D-related genes between COVID-19 patients with different degrees of disease severity.|Differences in vitamin D blood levels between COVID-19 patients in relation to mortality.|Differences in vitamin D blood levels between COVID-19 patients in relation to length of stay in hospitals.|Differences in vitamin D blood levels between COVID-19 patients in relation to duration of mechanical ventilation.|Differences in genetic variants in vitamin D-related genes between COVID-19 patients in relation to mortality.|Differences in genetic variants in vitamin D-related genes between COVID-19 patients in relation to length of stay in hospitals.|Differences in genetic variants in vitamin D-related genes between COVID-19 patients in relation to duration of mechanical ventilation.
NCT04482673 Vitamin D Supplementation in the Prevention and Mitigation of COVID-19 Infection Recruiting Phase 4 Jul/31/2020 Dec/31/2022
  • Alternative id - 00099939
  • Interventions - Drug: Daily Vitamin D3|Drug: Daily placebo|Drug: Bolus vitamin D3|Drug: Bolus placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Medical University of South Carolina, Charleston, South Carolina, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  • Enrollment - 140
  • Age - 50 Years and older   (Adult, Older Adult)
  • Outcome measures - Change in total circulating 25(OH)D concentration|Change in total circulating 25(OH)D concentration in COVID-19 positives|Change in SARS-CoV-2 antibody titers|Change in inflammatory cytokine concentration (10 cytokine panel Elisa: Interferon (INF)-gamma, Interleukin (IL)-1beta, IL-2, IL-3, IL-4, IL-6, IL-8, IL-10, IL-13, Tumor Necrosis Factor (TNF)-alpha|Respiratory symptoms|Signs and symptoms of rhino/sinusitis|NCI Dietary Intake|Charlson Comorbidity survey|Paffenberger Physical Activity Assessment|Perceived stress|Pandemic stress|NEO-Personality Inventory|GrassrootsHealth Monthly Health assessment
NCT04945577 The Relationship Between Vitamin D Levels, Inflammatory Parameters and Disease Severity of COVID-19 Infection Completed Jul/01/2020 Aug/01/2020
  • Alternative id - Gulcanozturk
  • Interventions - Diagnostic Test: Inflammatory Parameters|Other: 25 OH Vitamin D Level
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Gulcan Ozturk, Istanbul, Turkey
  • Study designs - Observational Model: Other|Time Perspective: Retrospective
  • Enrollment - 300
  • Age - 16 Years to 97 Years   (Child, Adult, Older Adult)
  • Outcome measures - 25-OH vitamin D|White blood cell count|neutrophil count|neutrophil ratio|lymphocyte count|lymphocyte ratio|platelet count|hemoglobin count|C-reactive protein levels|neutrophil to lymphocyte ratio|platelet to lymphocyte ratio
NCT04536298 Vitamin D and COVID-19 Trial Recruiting Phase 3 Dec/28/2020 Dec/31/2021
  • Alternative id - 2020P002815
  • Interventions - Dietary Supplement: vitamin D|Dietary Supplement: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Brigham and Women's Hospital, Boston, Massachusetts, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 2700
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Rate of seeking healthcare visits (including hospitalizations, emergency room visits, or ambulatory or virtual clinician visits) for symptoms or concerns related to COVID-19 or deaths in participants newly diagnosed with COVID-19 (index cases)|Rate of hospitalization/death or emergency room visits related to COVID-19 infection among index cases|Rate of hospitalization/death or emergency room visits related to COVID-19 in index cases with high risk for disease progression (defined as age 50 or older, or age 18-49 with at least one co-morbidity or risk factor)|Self-reported disease severity in index cases|Time to seeking healthcare (including hospitalizations, emergency room visits, or ambulatory or other clinician visits) or death in index cases|ICU admission/ventilation support in index cases|SARS-CoV-2 infection in close household contacts|Time to symptom onset and self-reported disease severity in household contacts|Rate of healthcare visits (including hospitalizations, emergency room visits, or ambulatory or other clinician visits) for symptoms or concerns related to COVID-19 infection or deaths among household contacts who contract COVID-19
NCT04979065 Nutrition, Immunity, and Covid-19 in Obese People Not yet recruiting Not Applicable Jul/24/2021 Jun/01/2022
  • Alternative id - NICO
  • Interventions - Dietary Supplement: Probiotics, Vitamin D|Other: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Human Nutrition Research Center, Indonesian Medical Education Research Institute (HNRC-IMERI) Faculty of Medicine, Universitas Indonesia, Jakarta Pusat, DKI Jakarta, Indonesia
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  • Enrollment - 80
  • Age - 20 Years to 65 Years   (Adult, Older Adult)
  • Outcome measures - Zonulin level|Vitamin D level|Nutritional status|Gut microbiota (optional)|Inflammation marker|Cathelicidin level|SARS COV-2|CD4/CD8 ratio|Covid-19 infection
NCT04734886 The Effect of Probiotic Supplementation on SARS-CoV-2 Antibody Response After COVID-19 Completed Not Applicable Nov/27/2020 Sep/13/2021
  • Alternative id - Provid
  • Interventions - Dietary Supplement: L. reuteri DSM 17938 + vitamin D|Dietary Supplement: Placebo + vitamin D
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Örebro University, Örebro, Örebro Län, Sweden
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science
  • Enrollment - 161
  • Age - 18 Years to 60 Years   (Adult)
  • Outcome measures - SARS-CoV-2 specific antibodies|Maintenance of SARS-CoV-2 seroconversion in seropositive individuals|Duration of COVID-19 symptoms measured by a weekly symptom questionnaire|Severity of COVID-19 symptoms measured by Ordinal Scale for Clinical Improvement (scale 0-7, a lower score corresponds to a better outcome)|Secretory IgA (sIgA) antibodies|Blood group A antigen antibodies|Blood group B antigen antibodies|Tn antigen antibodies|Innate immune system activation|Cytokines|Total antibodies|T cell activation|B cell activation|Intestinal inflammation|Intestinal barrier function|Indirect marker of intestinal permeability
NCT04868903 Low vs. Moderate to High Dose Vitamin D for Prevention of COVID-19 Recruiting Not Applicable Nov/30/2020 Dec/30/2022
  • Alternative id - UChicagoBSDIRB20-1302
  • Interventions - Dietary Supplement: Vitamin D3
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Rush University Medical Center, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  • Enrollment - 2000
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - SARS-CoV-2 infection as measured by patient report of clinically confirmed COVID-19 (or viral PCR when available)|SARS-CoV-2 antibody seroconversion confirmed by a COVID-19 antibody test
NCT04525820 High Dose Vitamin-D Substitution in Patients With COVID-19: a Randomized Controlled, Multi Center Study Active, not recruiting Not Applicable Dec/15/2020 Nov/30/2021
  • Alternative id - 2020-01401
  • Interventions - Drug: Single high dose vitamin D|Drug: Placebo|Drug: Treatment as usual vitamin D
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Cantonal Hospital Baselland Liestal, Liestal, BL, Switzerland|Cantonal Hospital St. Gallen, Saint Gallen, SG, Switzerland
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 80
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Length of hospitalization|Need of intensive care|Lenght of the Intensive Care Treatment|Overall mortality|Development of vitamin D levels|Development of sepsis
NCT04334512 A Study of Quintuple Therapy to Treat COVID-19 Infection Recruiting Phase 2 Jun/22/2020 Sep/01/2024
  • Alternative id - PRG-044
  • Interventions - Drug: Hydroxychloroquine|Drug: Azithromycin|Dietary Supplement: Vitamin C|Dietary Supplement: Vitamin D|Dietary Supplement: Zinc
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - ProgenaBiome, Ventura, California, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment
  • Enrollment - 600
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - The rate of recovery of mild or moderate COVID-19 in patients using Quintuple Therapy|Reduction or Progression of Symptomatic Days|Assess the safety of Quintuple Therapy|Assess the safety of Quintuple Therapy via pulse|Assess the safety of Quintuple Therapy via oxygen saturation|Assess the safety of Quintuple Therapy via EKG|Assess Tolerability of Quintuple Therapy
Export (.csv)